Servier’s Tibsovo (ivosidenib tablets) has received an expanded indication from the FDA, allowing its utilization in patients diagnosed with relapsed or refractory myelodysplastic syndromes that exhibit an IDH1 mutation. This new approval represents the fifth for Tibsovo, which is already recognized for its efficacy in acute myeloid leukemia (AML) and cholangiocarcinoma. This recent regulatory endorsement establishes Tibosovo as the premier and sole approved targeted therapy for a defined subset of relapsed or refractory myelodysplastic syndromes patients based on their molecular characteristics.
TIBSOVO, a precision medicine designed to target the specific mutati...
